Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by Peace13on Oct 02, 2020 3:55pm

287 Views

Post# 31659238

RE:Who's buying CMPS before the weekend?

Bugger off Blazefoley.
You post more on MMED than on CMPS.
Your pump is useless and annoying.

So people know, CMPS is down $6 from Sept.25.
And who wants to drop $35 a share when they can buy MMED at 1/43 of the price.
Will MMED triple within the next 6 weeks, you can bet the house on that.
Will CMPS triple with in the next 6 weeks, no way!
Choice is simple.
Mr.Wonderful say buy MMED. Yes indeed!

Bullboard Posts

Michael Gentile tops up stake in Astra Exploration